Compare Heron Therapeutics Inc (HRTX) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $70.25M), while Oruka Therapeutics Inc. Common Stock trades at $77.42 (market cap $5.08B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 72.3× Heron Therapeutics Inc's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HRTX | ORKA | |
|---|---|---|
Market Cap | $70.25M | $5.08B |
Volume | 2,092,253 | 685,276 |
Sector | Health | Health |
52-Week High | $1.49 | $113.08 |
52-Week Low | $0.27 | $26.19 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $176.99M | $4.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $20.20 million on $154.90 million revenue in 2025, with a negative net income margin of -22.52%. Recent Q2 2026 earnings missed expectations, posting a loss of $0.03 per share versus an expected loss of $0.005. Analyst consensus remains strongly positive with 17 buy ratings out of 19 total.
The outlook is mixed; strong analyst support and improving cash flow trends in 2026 suggest potential, but persistent losses and high valuation multiples like EV/EBITDA of 34.03 pose significant risks. Investment opportunity hinges on future profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
